tetano
Editor, Senior Moderator
PLoS One
. 2024 May 10;19(5):e0303244.
doi: 10.1371/journal.pone.0303244. eCollection 2024. Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers
Angélica Ramos[SUP] 1 2 3 [/SUP], Sandra Martins[SUP] 1 2 3 [/SUP], Ana Sofia Marinho[SUP] 1 [/SUP], Pedro Norton[SUP] 2 3 4 [/SUP], Maria João Cardoso[SUP] 1 [/SUP], João Tiago Guimarães[SUP] 1 2 3 5 [/SUP]
Affiliations
To predict protective immunity to SARS-CoV-2, cellular immunity seems to be more sensitive than humoral immunity. Through an Interferon-Gamma (IFN-γ) Release Assay (IGRA), we show that, despite a marked decrease in total antibodies, 94.3% of 123 healthcare workers have a positive cellular response 6 months after inoculation with the 2nd dose of BNT162b2 vaccine. Despite the qualitative relationship found, we did not observe a quantitative correlation between IFN-γ and IgG levels against SARS-CoV-2. Using stimulated whole blood from a subset of participants, we confirmed the specific T-cell response to SARS-CoV-2 by dosing elevated levels of the IL-6, IL-10 and TNF-α. Through a 20-month follow-up, we found that none of the infected participants had severe COVID-19 and that the first positive cases were only 12 months after the 2nd dose inoculation. Future studies are needed to understand if IGRA-SARS-CoV-2 can be a powerful diagnostic tool to predict future COVID-19 severe disease, guiding vaccination policies.
. 2024 May 10;19(5):e0303244.
doi: 10.1371/journal.pone.0303244. eCollection 2024. Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers
Angélica Ramos[SUP] 1 2 3 [/SUP], Sandra Martins[SUP] 1 2 3 [/SUP], Ana Sofia Marinho[SUP] 1 [/SUP], Pedro Norton[SUP] 2 3 4 [/SUP], Maria João Cardoso[SUP] 1 [/SUP], João Tiago Guimarães[SUP] 1 2 3 5 [/SUP]
Affiliations
- PMID: 38728294
- DOI: 10.1371/journal.pone.0303244
To predict protective immunity to SARS-CoV-2, cellular immunity seems to be more sensitive than humoral immunity. Through an Interferon-Gamma (IFN-γ) Release Assay (IGRA), we show that, despite a marked decrease in total antibodies, 94.3% of 123 healthcare workers have a positive cellular response 6 months after inoculation with the 2nd dose of BNT162b2 vaccine. Despite the qualitative relationship found, we did not observe a quantitative correlation between IFN-γ and IgG levels against SARS-CoV-2. Using stimulated whole blood from a subset of participants, we confirmed the specific T-cell response to SARS-CoV-2 by dosing elevated levels of the IL-6, IL-10 and TNF-α. Through a 20-month follow-up, we found that none of the infected participants had severe COVID-19 and that the first positive cases were only 12 months after the 2nd dose inoculation. Future studies are needed to understand if IGRA-SARS-CoV-2 can be a powerful diagnostic tool to predict future COVID-19 severe disease, guiding vaccination policies.